New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 28, 2014
07:29 EDTATNM, ESPR, TGTX, ZIOP, KBIO, HZNP, EBIO, OMER, FPRX, RGDO, DRNABioCentury to hold a conference
Future Leaders in the Biotech Industry Conference is being held in New York on March 28.
News For ATNM;RGDO;FPRX;OMER;EBIO;HZNP;KBIO;ZIOP;TGTX;ESPR;DRNA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 30, 2014
07:30 EDTATNMSachs Associates to hold a conference
14th Annual Biotech in Europe Forum for Global Partnering and Investment to be held in Basel, Switzerland on September 30-October 1.
07:07 EDTESPREsperion cholesterol drug a blockbuster if approved, says Citigroup
Citigroup believes Esperion's cholesterol lowering drug ETC-1002 is an inevitable blockbuster if approved. Citi views the company's market cap as disproportionate to the remaining risks around the drug. It says it continues to be a buyer of the stock and raised its price target for Esperion shares to $35 from $30.
September 26, 2014
09:09 EDTHZNPHorizon reports executive committee, commercial restructuring
Subscribe for More Information
08:49 EDTESPREsperion phase II trial likely to be successful, says Summer Street
Subscribe for More Information
07:32 EDTESPRBioCentury to hold a conference
21st Annual NewsMakers in the Biotech Industry Conference to be held in New York on September 26.
September 25, 2014
08:59 EDTESPRSummer Street chief scientific officer holds an analyst/industry conference call
Subscribe for More Information
05:57 EDTTGTXTG Therapeutics price target raised to $22 from $19 at Brean Capital
Brean Capital raised its price target for TG Therapeutics shares to $22 after the company acquired the rights to TGR-1202 from Rhizen Pharmaceuticals. The firm keeps a Buy rating on the stock.
September 24, 2014
16:57 EDTRGDORegado Biosciences announces 60% workforce reduction, exploring alternatives
Subscribe for More Information
September 23, 2014
17:02 EDTHZNPBalaji Venkataraman reports 15.6% stake in Horizon Pharma
Subscribe for More Information
07:54 EDTHZNPLeerink to hold a conference
Subscribe for More Information
07:34 EDTTGTXTG Therapeutics announces exercise of license option for TGR-1202
TG Therapeutics announced that it has exercised its option to license the global rights to TGR-1202, the company's novel, next generation PI3K-delta inhibitor from Rhizen Pharmaceuticals, S A. The company and Rhizen have to date been jointly developing TGR-1202 in a 50:50 joint venture. Given the successful development of TGR-1202, TG Therapeutics elected an early exercise of the company's license option. In exchange for the global license, Rhizen will receive a one-time, upfront cash payment of $4M and approximately 370,000 shares of TG Therapeutics' common stock. TG Therapeutics will receive exclusive worldwide rights, excluding India, for the development and commercialization of TGR-1202 for all indications. Rhizen will be eligible to receive regulatory filing, approval and sales based milestones in the aggregate of approximately $240M, and tiered royalties based on net sales.
September 19, 2014
16:57 EDTHZNPHorizon Pharma files automatic ordinary share shelf
10:46 EDTHZNPHorizon Pharma backs FY15 revenue view $380M-$405M, consensus $376.94M
Backs FYT15 adjusted EBITDA view $150M-$170M
10:45 EDTHZNPHorizon Pharma backs FY14 revenue view $270M-$280M, consensus $277.56M
Subscribe for More Information
September 18, 2014
19:50 EDTHZNPHorizon Pharma trading halted, pending news
Subscribe for More Information
09:19 EDTHZNPHorizon Pharma announces holder approval of Vidara acquisition
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use